Claims
- 1. A compound of the formula ##STR8## wherein: R.sub.1 and R.sub.2 are each, independently, hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, MeSO.sub.2, or together can form a 5-7 membered carbocyclic or heterocyclic ring;
- R.sub.3 is alkoxy, halogen, hydrogen or carbamoyl;
- R.sub.4 is hydrogen, hydroxy, lower alkyl, or lower alkoxy;
- R.sub.5 is hydrogen, lower alkyl, or halogen;
- R.sub.6 is hydrogen, lower alkyl, or phenyl;
- R.sub.7 is hydrogen, lower alkyl, lower alkoxy, halogen, CN, CF.sub.3, or hydroxy; and
- X is (CH.sub.2).sub.n,
- wherein n is 0 to 3; or pharmaceutically acceptable salts thereof.
- 2. A compound as in claim 1, wherein:
- R.sub.1 and R.sub.2 are each, independently, lower alkyl, lower alkoxy, halogen, or together can form a 5 to 7 membered carbocyclic or heterocyclic ring;
- R.sub.3 is alkoxy, halogen, hydrogen or carbamoyl;
- R.sub.4 is hydrogen or hydroxy;
- R.sub.5 is hydrogen;
- R.sub.6 is hydrogen or lower alkyl;
- R.sub.7 is halogen or CN; and
- X is (CH.sub.2).sub.n,
- wherein n is 0 to 3; or pharmaceutically acceptable salts thereof.
- 3. The compound of claim 1 which is [(cis)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-2-methoxy-phenoxy)-ethyl]-amine.
- 4. The compound of claim 1 which is [(trans)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(2-methoxy-phenoxy)-ethyl]-amine.
- 5. The compound of claim 1 which is [(1,4-cis)-4-(6-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(5-fluoro-2-methoxy-phenoxy)-ethyl]amine.
- 6. The compound of claim 1 which is [(1,4-trans)-4-(6-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(5-fluoro-2-methoxy-phenoxy)-ethyl]-amine.
- 7. The compound of claim 1 which is [(cis)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(2-(1H-indol-4-yloxy)ethyl]-amine.
- 8. The compound of claim 1 which is [(trans)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(2-(1H-indol-4-yloxy)ethyl]-amine.
- 9. The compound of claim 1 which is [(cis)-4-(1H-Indol-3-yl)-cyclohexyl]-[2-(2-(1H-indol-4-yloxy)ethyl]-amine.
- 10. The compound of claim 1 which is [(trans)-4-(1H-Indol-3-yl)-cyclohexyl]-[2-(2-(1H-indol-4-yloxy)ethyl]-amine.
- 11. The compound of claim 1 which is [2-(2,3)-Dihydro-benzo[1,4]dioxin-5-yloxy-ethyl]-[(1,4-cis)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 12. The compound of claim 1 which is [2,(2,3)-Dihydro-benzo[1,4]dioxin-5-yloxy-ethyl]-[(1,4-trans)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]amine.
- 13. The compound of claim 1 which is [2-(2,3)-Dihydro-benzo[1,4]dioxin-5-yloxy-ethyl]-[(1,4-cis)-4-(6-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 14. The compound of claim 1 which is [2-(2,3)-Dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-[(1,4-trans)-4-(6-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 15. The compound of claim 1 which is [2-(6-Fluorochroman-8-yloxy)-ethyl]-[(1,4-cis)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 16. The compound of claim 1 which is [2-(6-Fluorochroman-8-yloxy)-ethyl]-[(1,4-trans)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 17. The compound of claim 1 which is 3-{(1,4-cis)-4-[2-(6-Fluorochroman-8-yloxy)-ethylamino]-cyclohexyl}-1-methyl-1H-indol-5-carbonitrile.
- 18. The compound of claim 1 which is 3-{(1,4-cis)-4-[2-(6-Fluorochroman-8-yloxy)-ethylamino]-cyclohexyl}-1-methyl-1H-indol-5-carbonitrile.
- 19. The compound of claim 1 which is 3-{(1,4-trans)-4-[2-(6-Fluorochroman-8-yloxy)-ethylamino]-cyclohexyl}-1H-indol-5-carbonitrile.
- 20. The compound of claim 1 which is 3{(1,4-cis)-4-[2-(5-Fluoro-2,3-dihydro-benzofuran-7-yloxy)ethylamino]-cyclohexyl]}-1H-indol-5-carbonitrile.
- 21. The compound of claim 1 which is 3-{(1,4-trans)-4-[2-(5-Fluoro-2,3-dihydro-benzofuran-7-yloxy)ethylamino]-cyclohexyl}-1H-indol-5-carbonitrile.
- 22. The compound of claim 1 which is [2-(5-Fluoro-benzofuran-7-yloxy)-ethyl]-[(1,4-cis)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 23. The compound of claim 1 which is [2-(5-Fluoro-benzofuran-7-yloxy)-ethyl]-[(1,4-trans)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 24. The compound of claim 1 which is [2-(6-Chloro-1H-benzoimidazol-4-yloxy)-ethyl]-[(1,4-trans)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 25. The compound of claim 1 which is [2-(6-Chloro-2-methyl-1H-benzoimidazol-4-yloxy)-ethyl]-[(1,4-trans)-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 26. The compound of claim 1 which is [(1,4-cis)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(4-fluoro-2-methoxy-phenoxy)-ethyl]-amine.
- 27. The compound of claim 1 which is [(1,4-trans)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(4-fluoro-2-methoxy-phenoxy)-ethyl]-amine.
- 28. The compound of claim 1 which is [(1,4-trans)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexylmethyl]-[2-(2-methoxy-phenoxy)-ethyl]-amine.
- 29. The compound of claim 1 which is 3-(4-{[2-(methoxy-phenoxy)-ethylamino]-methyl}-cyclohexyl)-1H-indol-5-carbonitrile.
- 30. The compound of claim 1 which is (1,4-cis)-[2-(4,5-Difluoro-2-methoxy-phenoxy)-ethyl]-{4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 31. The compound of claim 1 which is (1,4-trans)-[2-(4,5-Difluoro-2-methoxy-phenoxy)-ethyl]-[1-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-amine.
- 32. The compound of claim 1 which is [(1,4-trans)-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-[2-(5-fluoro-4-methane sulfonyl-2-methoxy-phenoxy)-ethyl]-amine.
- 33. The compound of claim 1 which is (1,4)-4-(5-Fluoro-1H-indol-3-yl)-1-}[2-(1H-indol-4-yloxy)-ethylamino]-methyl}-cyclohexanol.
- 34. A pharmaceutical composition comprising a compound of the formula: ##STR9## wherein: R.sub.1 and R.sub.2 are each, independently, hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, MeSO.sub.2, or together can form a 5-7 membered carbocyclic or heterocyclic ring;
- R.sub.3 is alkoxy, halogen, hydrogen or carbamoyl;
- R.sub.4 is hydrogen, hydroxy, lower alkyl, or lower alkoxy;
- R.sub.5 is hydrogen, lower alkyl, or halogen;
- R.sub.6 is hydrogen, lower alkyl, or phenyl;
- R.sub.7 is hydrogen, lower alkyl, lower alkoxy, halogen, CN, CF.sub.3, or hydroxy; and
- X is (CH.sub.2).sub.n,
- wherein n is 0 to 3; or pharmaceutically acceptable salts thereof.
- 35. A method for alleviating the symptoms of depression in a patient in need thereof comprising administering to said patient an antidepressant effective amount of a compound of the formula: ##STR10## wherein: R.sub.1 and R.sub.2 are each, independently, hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, MeSO.sub.2, or together can form a 5-7 membered carbocyclic or heterocyclic ring;
- R.sub.3 is alkoxy, halogen, hydrogen or carbamoyl;
- R.sub.4 is hydrogen, hydroxy, lower alkyl, or lower alkoxy;
- R.sub.5 is hydrogen, lower alkyl, or halogen;
- R.sub.6 is hydrogen, lower alkyl, or phenyl;
- R.sub.7 is hydrogen, lower alkyl, lower alkoxy, halogen, CN, CF.sub.3, or hydroxy; and
- X is (CH.sub.2).sub.n,
- wherein n is 0 to 3; or pharmaceutically acceptable salts thereof.
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Ser. No. 60/093,052, which was converted from U.S. patent application Ser. No. 09/057,307, filed Apr. 8, 1998, pursuant to a petition filed under 37 C.F.R. 1.53(c)(2)(i) filed Jul. 30, 1998.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
3371098 |
Kralt et al. |
Feb 1968 |
|
5436264 |
Pfister et al. |
Jul 1995 |
|
5468767 |
Cipollina et al. |
Nov 1995 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
20722941 |
Jul 1996 |
EPX |
5125024 |
May 1993 |
JPX |
5255302 |
Oct 1993 |
JPX |
9040648 |
Feb 1997 |
JPX |
WO9808817 |
Mar 1998 |
WOX |
WO9808819 |
Mar 1998 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Le Poul et al., Arch. Pharmacol., 352:141 (1995). |
Artigas et al., Trends Neurosci., 19:378-383 (1996). |